Boost ROI through targeted therapies, novel drug delivery, strategic research partnerships, and retail pharmacy expansion, guided by actionable regional and segment insights.
Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Angina Pectoris Drugs Market Size, Share & Trends Analysis Report 2026-2033" has been added to ResearchAndMarkets.com's offering.
The global angina pectoris drugs market was valued at USD 12.9 billion in 2025 and is projected to increase from USD 13.4 billion in 2026 to USD 17.6 billion by 2033. The market is expected to expand at a CAGR of 4.0% from 2026 to 2033, supported by the rising prevalence of cardiovascular diseases, advances in personalized cardiovascular medicine, and the development of novel drug delivery systems.
North America dominated the global angina pectoris drugs market in 2025, accounting for 40.0% of Total Fina Elf revenue. The region's leadership is supported by established healthcare infrastructure, access to advanced cardiology treatments, significant pharmaceutical research activity, and the adoption of innovative therapies. Continued clinical development and regulatory approvals are expected to reinforce regional demand throughout the forecast period.
Increasing cases of coronary heart disease and other cardiac disorders are creating sustained demand for effective angina treatments worldwide. Pharmaceutical companies are investing in clinical trials and research programs designed to improve treatment efficacy, safety, and patient outcomes. Advances in transdermal patches, sustained-release formulations, and other drug delivery technologies are also improving medication administration and patient compliance.
The expanding geriatric population represents another important market driver, as older adults have a higher risk of cardiovascular disease and related complications. This demographic trend is encouraging the development of targeted therapies that address age-specific treatment requirements. Strategic partnerships between pharmaceutical companies, biotechnology organizations, and research institutions are further accelerating drug discovery, formulation development, and commercialization.
Additional market opportunities are emerging from continued innovation in cardiology, a growing number of drug approvals from regulatory agencies such as the FDA, and the expansion of retail and online pharmacy networks. Retail pharmacies remain an important purchasing channel for angina medications, while online pharmacies are gaining relevance as healthcare access and digital commerce continue to evolve.
Market Segmentation
The report provides global, regional, and country-level revenue forecasts and evaluates industry trends and opportunities across major market segments from 2021 to 2033. The angina pectoris drugs market is analyzed by type, drug class, distribution channel, and region.
Type Outlook (Revenue, USD Billion, 2021 - 2033)
Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
Key Benefits of the Report
The report offers market intelligence for pharmaceutical companies, healthcare organizations, investors, and other stakeholders seeking to evaluate the future of the angina pectoris drugs market. Its analysis of treatment innovation, demographic trends, regulatory activity, competitive positioning, and regional performance supports informed decision-making in a market expected to maintain steady growth through 2033.
Key Topics Covered:
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Angina Pectoris Drugs Market Analysis Tools
3.4.1. Porter's Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Angina Pectoris Drugs Market: Type Movement Analysis, 2026 & 2033 (USD Million)
4.3. Stable Angina
4.3.1. Stable Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Unstable Angina
4.4.1. Unstable Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Microvascular Angina
4.5.1. Microvascular Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Prinzmetal Angina
4.6.1. Prinzmetal Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Angina Pectoris Drugs Market: Drug Class Movement Analysis, 2026 & 2033 (USD Million)
5.3. Beta Blockers
5.3.1. Beta Blockers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Calcium Antagonists
5.4.1. Calcium Antagonists Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Nitrates
5.5.1. Nitrates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Anticoagulants
5.6.1. Anticoagulants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Anti-Platelets
5.7.1. Anti-Platelets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Other Drug Classes
5.8.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Angina Pectoris Drugs Market: Distribution Channel Movement Analysis, 2026 & 2033 (USD Million)
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Retail Pharmacy
6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Online Pharmacy
6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis
7.1. Angina Pectoris Drugs Market Share, Region, 2026 & 2033 (USD Million)
7.2. North America
7.2.1. North America Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Europe
7.3.1. Europe Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.2. UK
7.3.2.1. UK Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.4. France
7.3.4.1. France Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. China
7.4.3.1. China Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. India
7.4.4.1. India Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Latin America
7.5.1. Latin America Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Pfizer .
8.4.1.1. Participant's Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/Strategic Initiatives
8.4.2. Bayer AG
8.4.2.1. Participant's Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/Strategic Initiatives
8.4.3. Astrazeneca
8.4.3.1. Participant's Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/Strategic Initiatives
8.4.4. Gilead Sciences
8.4.4.1. Participant's Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/Strategic Initiatives
8.4.5. Novartis AG
8.4.5.1. Participant's Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/Strategic Initiatives
8.4.6. GlaxoSmithKline .
8.4.6.1. Participant's Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/Strategic Initiatives
8.4.7. Merck KGaA & Co., Inc.
8.4.7.1. Participant's Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/Strategic Initiatives
8.4.8. Amgen .
8.4.8.1. Participant's Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/Strategic Initiatives
8.4.9. Eli Lilly and Company
8.4.9.1. Participant's Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/Strategic Initiatives
8.4.10. Otsuka Pharmaceutical Co., Ltd.
8.4.10.1. Participant's Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/Strategic Initiatives
8.4.11. Sanofi S.A.
8.4.11.1. Participant's Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/Strategic Initiatives
8.4.12. Boehringer Ingelheim International GmbH
8.4.12.1. Participant's Overview
8.4.12.2. Financial Performance
8.4.12.3. Product Benchmarking
8.4.12.4. Recent Developments/Strategic Initiatives
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/2tuhib
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900